BCSCDB: Biomarkers of Cancer Stem Cells Database
Number of entries related to 5637 cell line is 128
| GENE | HGNC_ID | MARKER_TYPE | CANCER_TYPE | HISTOLOGICAL_TYPE | CELL_LINE | CSC_ENRICHMENT | METHOD | EXPRESSION_LEVEL | CONFIDENCE_SCORING | GLOBAL_SCORING | PUBMED_ID |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AFF4 | 17869 | LTM | Bladder Cancer | Carcinoma | 5637 | NA | qRT-PCR followed by Western Blotting | NA | 0.48 | 0.0032 | 32676121 |
| METTL3 | 17563 | LTM | Bladder Cancer | Carcinoma | 5637 | NA | qRT-PCR followed by Western Blotting | NA | 0.48 | 0.0011 | 32676121 |
| ALDH1A1 | 402 | LTM | Bladder Cancer | Carcinoma | 5637 | NA | ALDEFLUOR assay followed by Western Blotting | NA | 0.4 | 0.684 | 30349299 |
| ALDH1A1 | 402 | LTM | Bladder Cancer | Carcinoma | 5637 | Paclitaxel | SFA followed by Western Blotting | NA | 0.4 | 0.684 | 35008872 |
| ALDH1A1 | 402 | LTM | Bladder Cancer | Carcinoma | 5637 | NA | SFA followed by qRT-PCR | NA | 0.4 | 0.684 | 30592142 |
| ALDH1A1 | 402 | LTM | Bladder Cancer | Carcinoma | 5637 | NA | ALDEFLUOR assay | NA | 0.4 | 0.684 | 28445934 |
| ALDH1A1 | 402 | LTM | Bladder Cancer | Carcinoma | 5637 | Cisplatin | ALDEFLUOR assay followed by CFA | NA | 0.4 | 0.684 | 22399585 |
| ALDH1A1 | 402 | LTM | Bladder Cancer | Carcinoma | 5637 | NA | ALDEFLUOR assay followed by SFA | NA | 0.4 | 0.684 | 32676121 |
| ABCG2 | 74 | LTM | Bladder Cancer | Carcinoma | 5637 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.1739 | 29559853 |
| CD24 | 1645 | LTM | Bladder Cancer | Carcinoma | 5637 | NA | Western Blotting followed by SFA | NA | 0.28 | 0.456 | 30327565 |
| CD44 | 1681 | LTM | Bladder Cancer | Carcinoma | 5637 | NA | SFA followed by Western Blotting | NA | 0.28 | 1 | 29559853 |
| CD44 | 1681 | LTM | Bladder Cancer | Carcinoma | 5637 | NA | SFA followed by qRT-PCR | NA | 0.28 | 1 | 30327565 |
| CD44 | 1681 | LTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs | NA | 0.28 | 1 | 29340052 |
| CD44 | 1681 | LTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs followed by SFA | NA | 0.28 | 1 | 21964864 |
| CD44 | 1681 | LTM | Bladder Cancer | Carcinoma | 5637 | NA | MACs | NA | 0.28 | 1 | 32192892 |
| CD44 | 1681 | LTM | Bladder Cancer | Carcinoma | 5637 | NA | SFA followed by FACs | NA | 0.28 | 1 | 32388699 |
| CTNNB1 | 2514 | LTM | Bladder Cancer | Carcinoma | 5637 | Paclitaxel | SFA followed by Western Blotting | NA | 0.28 | 0.0647 | 35008872 |
| KLF4 | 6348 | LTM | Bladder Cancer | Carcinoma | 5637 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0891 | 29559853 |
| POU5F1 | 9221 | LTM | Bladder Cancer | Carcinoma | 5637 | Paclitaxel | SFA followed by Western Blotting | NA | 0.28 | 0.6448 | 35008872 |
| POU5F1 | 9221 | LTM | Bladder Cancer | Carcinoma | 5637 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.6448 | 29559853 |
| POU5F1 | 9221 | LTM | Bladder Cancer | Carcinoma | 5637 | NA | SFA followed by qRT-PCR | NA | 0.28 | 0.6448 | 30592142 |
| PROM1 | 9454 | LTM | Bladder Cancer | Carcinoma | 5637 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.7582 | 29559853 |
| PROM1 | 9454 | LTM | Bladder Cancer | Carcinoma | 5637 | NA | SFA followed by qRT-PCR | NA | 0.28 | 0.7582 | 30592142 |
| PROM1 | 9454 | LTM | Bladder Cancer | Carcinoma | 5637 | NA | MACs | NA | 0.28 | 0.7582 | 30746788 |
| PROM1 | 9454 | LTM | Bladder Cancer | Carcinoma | 5637 | NA | SFA followed by FACs | NA | 0.28 | 0.7582 | 32388699 |
| SOX2 | 11195 | LTM | Bladder Cancer | Carcinoma | 5637 | Paclitaxel | SFA followed by Western Blotting | NA | 0.28 | 0.5695 | 35008872 |
| SOX4 | 11200 | LTM | Bladder Cancer | Carcinoma | 5637 | NA | Western Blotting | NA | 0.28 | 0.0042 | 26681916 |
| YAP1 | 16262 | LTM | Bladder Cancer | Carcinoma | 5637 | NA | Western Blotting | NA | 0.28 | 0.0117 | 30349299 |
| YAP1 | 16262 | LTM | Bladder Cancer | Carcinoma | 5637 | NA | SFA followed by qRT-PCR | NA | 0.28 | 0.0117 | 30327565 |
| ABCB1 | 40 | LTM | Bladder Cancer | Carcinoma | 5637 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0604 | 30592142 |
| JARID2 | 6196 | LTM | Bladder Cancer | Carcinoma | 5637 | NA | qRT-PCR | NA | 0.2 | 0.0032 | 28445934 |
| NANOG | 20857 | LTM | Bladder Cancer | Carcinoma | 5637 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.5461 | 30592142 |
| XIST | 12810 | LTM | Bladder Cancer | Carcinoma | 5637 | NA | SFA followed by qPCR | NA | 0.2 | 0.0021 | 29559853 |
| ABCA1 | 29 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 30592142 |
| ALOX5AP | 436 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| AQP3 | 636 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 29340052 |
| ARPC3 | 706 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29340052 |
| ASS1 | 758 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0042 | 29340052 |
| ATF3 | 785 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| B3GNT7 | 18811 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| BACH2 | 14078 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| BLMH | 1059 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0053 | 29340052 |
| BORA | 24724 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29340052 |
| C3 | 1318 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 30592142 |
| C5orf46 | 33768 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| CDH2 | 1759 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0085 | 30592142 |
| CDKN2B | 1788 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| CKAP2L | 26877 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29340052 |
| CLASP2 | 17078 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| CLDN4 | 2046 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0042 | 29340052 |
| CLEC2B | 2053 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 30592142 |
| CMPK1 | 18170 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29340052 |
| COL13A1 | 2190 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29340052 |
| CREBRF | 24050 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| CXCL11 | 10638 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 30592142 |
| CXORF49 | 30891 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| CYP1A1 | 2595 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 29340052 |
| DAPP1 | 16500 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 29340052 |
| DDX60 | 25942 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 30592142 |
| DHRS3 | 17693 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 30592142 |
| DNAJC19 | 30528 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29340052 |
| EGR1 | 3238 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0074 | 29340052 |
| EHF | 3246 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0053 | 29340052 |
| EIF4A2 | 3284 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29340052 |
| ELF3 | 3318 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0042 | 29340052 |
| EPGN | 17470 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 29340052 |
| FADD | 3573 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| FAM229B | 33858 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29340052 |
| GALNT5 | 4127 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 29340052 |
| GSPT2 | 4622 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29340052 |
| H2AC20 | 4738 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| H2BC21 | 4760 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0042 | 29340052 |
| H2BC9 | 4755 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29340052 |
| HSPA6 | 5239 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0053 | 29340052 |
| HSPA7 | 5240 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| IFI44 | 16938 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 30592142 |
| IL1RN | 6000 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0053 | 29340052 |
| IL23A | 15488 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| IL24 | 11346 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 30592142 |
| IL36G | 15741 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| IL37 | 15563 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| IL7R | 6024 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 30592142 |
| IL8 | 6025 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0159 | 30592142 |
| ITGB4 | 6158 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0074 | 29340052 |
| KRT23 | 6438 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 29340052 |
| KRT6B | 6444 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 29340052 |
| LRRN1 | 20980 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| MAGOH | 6815 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| MT1X | 7405 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 29340052 |
| MTUS1 | 29789 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 29340052 |
| MUC16 | 15582 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 29340052 |
| MUC4 | 7514 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| NDUFB1 | 7695 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| NDUFB3 | 7698 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| NUCKS1 | 29923 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29340052 |
| NUP210 | 30052 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| OVOL1 | 8525 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 29340052 |
| PAG1 | 30043 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 30592142 |
| PDGFC | 8801 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29340052 |
| PI3 | 8947 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 30592142 |
| PIN4 | 8992 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| PNMA2 | 9159 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| PTGS2 | 9605 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0064 | 29340052 |
| RDH10 | 19975 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 30592142 |
| RPL35A | 10345 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29340052 |
| RPS25 | 10413 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29340052 |
| SAV1 | 17795 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| SCARNA14 | 32571 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| SCARNA20 | 32578 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| SCD | 10571 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0127 | 30592142 |
| SERPINA1 | 8941 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29340052 |
| SLC14A1 | 10918 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 30592142 |
| SLITRK6 | 23503 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 30592142 |
| SNORA12 | 32600 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| SNORA21 | 32611 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| SNORA23 | 32613 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| SNORA63 | 10106 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| SORBS2 | 24098 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 29340052 |
| SPEN | 17575 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| SPRR1B | 11260 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0042 | 29340052 |
| SPRR2A | 11261 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| SPRR2D | 11264 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| SPRR2E | 11265 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 29340052 |
| SPRR2F | 11266 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| TFRC | 11763 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0053 | 29340052 |
| TNFAIP2 | 11895 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| UBE2K | 4914 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| UNG | 12572 | HTM | Bladder Cancer | Carcinoma | 5637 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29340052 |